Laurus Labs Limited (LAURUSLABS)
ISIN: INE947Q01028 Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
590.55
-0.4(-0.07%)

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.

Pricing Updates

TODAY'S HIGH

605.5

TODAY'S LOW

589

52 WEEK HIGH

695.95

52 WEEK LOW

436.8

Major Holders

% of Shares Held by
All Insider

37.58%

% of Shares Held by
Institutions

23.00%

% of Float Held by
Institutions

36.84%

Number of Institutions
Holding Shares

75

Company Overview

MARKET CAP

31733.73 Cr.

ETERPRISE VALUE

32131.18 Cr.

NO. OF SHARES

53.73 Cr.

BOOK VALUE

62.364

DIV. YIELD

1.2%

DEBT

1776.66 Cr.

GROSS PROFIT

2686.75 Cr.

CASH

75.94 Cr.

REVENUE

5196 Cr.

REVENUE/SHARE

96.771

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments-27.60 Cr.-27.60 Cr.-27.60 Cr.-27.60 Cr.
Change To Liabilities-301.21 Cr.559.52 Cr.112.26 Cr.186.17 Cr.
Total cashflows from Investing Activities-914.34 Cr.-940.99 Cr.-221.13 Cr.-252.87 Cr.
Net Borrowings196.81 Cr.380.40 Cr.-5.82 Cr.56.41 Cr.
Total Cash from Financing Activities30.26 Cr.254.70 Cr.-127.66 Cr.-44.77 Cr.
Other Liabilities185.51 Cr.30.33 Cr.-23.45 Cr.15.56 Cr.
Total Assets4.31 Cr.7.38 Cr.2.61 Cr.2.43 Cr.
Net Income827.52 Cr.983.58 Cr.255.27 Cr.93.76 Cr.
Change in Cash26.89 Cr.46.77 Cr.-1.28 Cr.-3.60 Lakhs
Effect of Exchange Rate-13 Lakhs6 Lakhs9 Lakhs-5.30 Lakhs
Total Cash from Operating Activities911.10 Cr.733 Cr.347.42 Cr.297.66 Cr.
Depreciation251.49 Cr.201.38 Cr.183.46 Cr.160.49 Cr.
Other Cashflows from Investing Activities-10.02 Cr.1.17 Cr.90 Lakhs88.40 Lakhs
Dividends Paid-85.86 Cr.-75.04 Cr.-32 Cr.-15.90 Cr.
Change to Inventory-174.33 Cr.-660.17 Cr.-223.23 Cr.-96.90 Cr.
Change to Account Receivables-51.58 Cr.-523.74 Cr.-65.34 Cr.-149.28 Cr.
Other Cashflows from Financing Activities-85 Cr.-58.04 Cr.-92.45 Cr.-87.71 Cr.
Change to Net Income173.70 Cr.138.41 Cr.104.64 Cr.84.16 Cr.
Capital Expenditures-876.84 Cr.-688.77 Cr.-222.19 Cr.-254.26 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax1083.65 Cr.1301.11 Cr.293.61 Cr.119.75 Cr.
Minority Interest7.86 Cr.3.15 Cr.3.15 Cr.3.15 Cr.
Net Income1170.94 Cr.1350.65 Cr.383.15 Cr.214.93 Cr.
Selling General Administrative501.53 Cr.438.01 Cr.355.41 Cr.303.68 Cr.
Gross Profit2741.80 Cr.2614.48 Cr.1385.61 Cr.1027.46 Cr.
Ebit1170.94 Cr.1350.65 Cr.383.15 Cr.214.93 Cr.
Operating Income1170.94 Cr.1350.65 Cr.383.15 Cr.214.93 Cr.
Other Operating Expenses817.84 Cr.620.75 Cr.459.78 Cr.344.65 Cr.
Interest Expense-102.39 Cr.-56.12 Cr.-73.39 Cr.-74.23 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense251.42 Cr.317.29 Cr.38.34 Cr.25.98 Cr.
Total Revenue4935.57 Cr.4813.51 Cr.2831.72 Cr.2291.91 Cr.
Total Operating Expenses3764.63 Cr.3462.86 Cr.2448.57 Cr.2076.98 Cr.
Cost of Revenue2193.77 Cr.2199.03 Cr.1446.11 Cr.1264.45 Cr.
Total Other Income Expense Net-87.29 Cr.-49.54 Cr.-89.54 Cr.-95.18 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.832.23 Cr.983.82 Cr.255.27 Cr.93.76 Cr.
Net Income Applicable to Common Shares827.52 Cr.983.58 Cr.255.27 Cr.93.76 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets10.83 Cr.9.32 Cr.9.75 Cr.12.13 Cr.
Capital Surplus0694.77 Cr.685.20 Cr.678.66 Cr.
Total Liabilities3608.99 Cr.3149.99 Cr.1980.55 Cr.1772.77 Cr.
Stock Holder Equity3351.19 Cr.2597.55 Cr.1769.77 Cr.1558.40 Cr.
Minority Interest7.86 Cr.3.15 Cr.00
Other Liabilities647.46 Cr.225.12 Cr.162.60 Cr.142.07 Cr.
Total Assets6968.04 Cr.5750.69 Cr.3750.32 Cr.3331.18 Cr.
Common Stock107.47 Cr.107.32 Cr.106.91 Cr.106.43 Cr.
Retained Earnings01883.29 Cr.987.59 Cr.771.12 Cr.
Other Liabilities292.01 Cr.237.41 Cr.102.59 Cr.90.16 Cr.
Good Will246.30 Cr.246.30 Cr.9.74 Cr.9.73 Cr.
Treasury Stock3243.72 Cr.-87.83 Cr.-9.93 Cr.2.18 Cr.
Other Assets126.93 Cr.139.63 Cr.141.33 Cr.126.12 Cr.
Cash75.94 Cr.48.46 Cr.1.74 Cr.3.02 Cr.
Current Liabilities2681.01 Cr.2457.15 Cr.1692.38 Cr.1423.90 Cr.
Long Term Asset Charges0073.93 Cr.53.38 Cr.
Short Long Term Debt1135.69 Cr.137.92 Cr.101.34 Cr.93.01 Cr.
Other Stockholder Equity3243.72 Cr.-87.83 Cr.-9.93 Cr.2.18 Cr.
Property Plant Equipment3208.56 Cr.2277.17 Cr.1774.03 Cr.1716.83 Cr.
Total Cur. Assets3344.61 Cr.3074.86 Cr.1812.06 Cr.1462.95 Cr.
Long Term Investments30.81 Cr.3.41 Cr.3.41 Cr.3.40 Cr.
Net Tangible Assets3094.06 Cr.2341.93 Cr.1750.28 Cr.1536.53 Cr.
Short Term Investments0000
Net Receivables1354.82 Cr.1345.71 Cr.831.17 Cr.731.33 Cr.
Long Term Debt596.34 Cr.429.16 Cr.165.02 Cr.258.71 Cr.
Inventory1760.30 Cr.1575.45 Cr.905.22 Cr.681.93 Cr.
Accounts Payable876.37 Cr.1178.69 Cr.615.63 Cr.488.31 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account